Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

Outlook Therapeutics Inc.

The latest announcement is out from Outlook Therapeutics ( ($OTLK) ). On March 16, 2026, Outlook Therapeutics entered into a Note Purchase Agreemen...

Outlook Therapeutics Refinances Debt, Extends Note Maturities

Outlook Therapeutics ( ($OTLK) ) has issued an update. On March 6, 2026, Outlook Therapeutics’ board accepted the resignation of director Dr. Julia...

Outlook Therapeutics Announces Board Resignation and Size Reduction

The latest update is out from Outlook Therapeutics ( ($OTLK) ). At its annual meeting held on March 10, 2026, Outlook Therapeutics shareholders ele...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OTLK	$0.24	+13.43%	15.70M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OTLK	$0.24	+13.4%	15.70M
3
4
5
6

OTLK

OTLK

Get Outlook Therapeutics Inc. Data in Excel

Get Outlook Therapeutics Inc. Data in Excel